Almindelige bivirkninger, der førte til behandlingsstop af bortezomib og Caelyx inkluderede PPE, neuralgi, perifer neuropati, perifer sanseneuropati, thrombocytopeni, fald i ejektionsfraktion og træthed.
Common adverse events which led to treatment discontinuation of bortezomib and Caelyx included PPE, neuralgia, peripheral neuropathy, peripheral sensory neuropathy, thrombocytopaenia, decreased ejection fraction, and fatigue.